Euro Surveillance 2014;19(47):pii=20970, p.31-37
dos Santos et al. BMC Public Health 2014, 14:80 http://www.biomedcentral.com/1471-2458/14/80
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Introduction
Chapter A.10
African Health Sciences 2013; 13(2): 219 - 232 http://dx.doi.org/10.4314/ahs.v13i2.4
This module should always be used together with the
mhGAP Intervention Guide for Mental, Neurological
and Substance Use Disorders in Non-specialized Health
Settings (WHO, 2010), which outlines relevant general
principles of care and management of a range of other
mental, neurological and substa...nce use disorders.
(www.who.int/mental_health/publications/mhGAP_
intervention_guide/en/index.html)
In the future, this module may be integrated with other
products in the following ways:
– This module may be integrated – in its full form –
into future iterations of the existing mhGAP Intervention
Guide.
– The module will be integrated –in a simplified structure –
into a new product, the WHO-UNHCR mhGAP Intervention
Guide for Humanitarian Settings (planned for 2014).
more
The Access to Controlled Medications Programme identified the development of treatment guidelines that cover the treatment of all types of pain as one of the core areas of focus for improving access to opioid analgesics. Such guidelines are interesting both for health-care professionals and policy-...makers. They are also important in improving access to controlled medicines for determining when those opioid medicines and when non-opioid medicines are preferred.
Based on a Delphi study, WHO planned the development of three treatment guidelines, covering chronic pain in children, chronic pain in adults and acute pain.
more
Division of Global Migration and Quarantine
April 16, 2012